Lyell Immunopharma

Yahoo Finance • 2 months ago

Lyell Immunopharma CEO Seely sells shares worth $8k

Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely sold a total of 797 shares of common stock on August 11 and 12, 2025. The sales, which covered tax withholding obligations from vested restricted stock units, amounted to $8,312... Full story

Yahoo Finance • 2 months ago

Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314

LYELL IMMUNOPHARMA INC (NASDAQ:LYEL [https://www.chartmill.com/stock/quote/LYEL]) REPORTS Q2 2025 EARNINGS: NARROWER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Lyell Immunopharma Inc released its second-quarter 2025 financial results,... Full story

Yahoo Finance • 2 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients w... Full story

Yahoo Finance • 3 months ago

Lyell Immunopharma registers 625,000 shares for resale

* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) registers 625,000 common shares for resale by selling stockholders. * Shares were issued as additional merger consideration under the October 2024 merger agreeme... Full story

Yahoo Finance • 3 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright HCW@Home Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its... Full story

Yahoo Finance • 3 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its... Full story

Yahoo Finance • 4 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete r... Full story

Yahoo Finance • 4 months ago

Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments

* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) Monday announced [https://seekingalpha.com/pr/20130757-lyell-immunopharma-strengthens-clinical-and-commercial-capabilities-with-key-board-and] the appointment of M... Full story

Yahoo Finance • 4 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vic... Full story

Yahoo Finance • 5 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th In... Full story

Yahoo Finance • 6 months ago

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March... Full story

Yahoo Finance • 7 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL)Presented positive i... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today an... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinica... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announc... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today an... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today an... Full story

Yahoo Finance • 3 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestonesPhase 1 clinical trials initiated for two wholly-owned product can... Full story

Yahoo Finance • 3 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announc... Full story

Yahoo Finance • 3 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announc... Full story